Take your molecule from DNA to tox drug substance in only 10 months* and IND in 15 months*
Recombinant proteins that do not contain an Fc region, or have an affinity resin available, typically do not fit platform methods developed for mAb-type products. They often have product-specific requirements that impact the development strategy.
Benefit from Lonza’s experienced project teams and subject matter experts with a wealth of knowledge from working on these types of molecules, who can tailor a development strategy to meet your product-specific needs.
*From DNA transfection to Delivery of IND-Enabling CMC Modules. Indicative timelines. Subject to molecule evaluation and terms & conditions.
